Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

NETWORK 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 2Tumor-Agnostic 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 222Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × AEG 35156 × Clear all
NCT00357747 2023-08-04

AEG35156 and Docetaxel in Treating Patients With Solid Tumors

Canadian Cancer Trials Group

Phase 1 Completed
10 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00372736 2023-08-04

AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors

Canadian Cancer Trials Group

Phase 1 Completed
27 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00385775 2008-08-21

Study of XIAP Antisense for Advanced Cancers

Aegera Therapeutics

Phase 1 Terminated
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡